Mycobacteriumpyrazinamide

Ananthi Rajendran1, Ahmed Kabir Refaya1, Kannan Palaniyandi1

  • 1Department of Immunology, ICMR-National Institute for Research in Tuberculosis.

概括

结核病中皮拉津胺耐药性与pncA突变和广泛的转录基因变化有关. 这项研究揭示了耐药Mycobacterium结核病的适应性途径,为未来的治疗提供了洞察力.